A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Open to people ages 30 years and up

(sporadic CAA patients):

• Is 50 years or older
• Has probable CAA per the Boston Criteria Version 2.0

Inclusion Criteria (Dutch-type CAA patients):

• Is 30 years or older
• Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA

• Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)
• Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study
• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×upper limit of normal (ULN) at Screening
• Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² at Screening
• Has recently received an investigational agent
• Has had treatment with amyloid-targeting antibody

Note: other protocol defined inclusion / exclusion criteria apply